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House dust mite-derived proteases contribute to
allergic disorders in part by disrupting epithelial
barrier function. Interleukin-33 (IL-33), produced by
lung cells after exposure to protease allergens, can
induce innate-type airway eosinophilia by activating
natural helper (NH) cells, a member of group 2 innate
lymphoid cells (ILC2), to secrete Th2 type-cytokines.
Because IL-33 also can induce mast cells (MCs)
to secrete Th2 type-cytokines, MCs are thought
to cooperate with NH cells in enhancing protease
or IL-33-mediated innate-type airway eosinophilia.
However, we found that MC-deficient KitW-sh/W-sh
mice exhibited exacerbated protease-induced lung
inflammation associated with reduced numbers of
regulatory T (Treg) cells. Moreover, IL-2 produced
by IL-33-stimulated MCs promoted expansion of
numbers of Treg cells, thereby suppressing develop-ment of papain- or IL-33-inducedairwayeosinophilia.
We have thus identified a unique anti-inflammatory
pathway that can limit induction of innate-type
allergic airway inflammation mediated by NH cells.
INTRODUCTION
House dust mites (HDMs) are a major source of allergens in pa-
tients with allergic disorders such as atopic dermatitis, asthma,
and rhinitis (Gregory and Lloyd, 2011), and administration of
HDM extracts to mice causes allergic airway inflammation with
similarities to that seen in asthma (Johnson et al., 2004). HDM-
derived antigens can induce barrier disruption of lung epithelial
cells, thereby facilitating allergen sensitization that is dependent
on Toll-like receptor 4 (TLR4) (Hammad et al., 2009; Trompette
et al., 2009). In particular, HDM-derived cysteine proteases such
as Der p1 can disrupt the tight junctions between epithelial cells,
which are thought to contribute to development of allergic disor-
ders (Herbert et al., 1995;Nakamura et al., 2006;Wan et al., 1999).Immunity 43, 175–186, July 21, 2015 ª2015 Elsevier Inc. 175
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Figure 1. Lung Natural Helper Cells Con-
tribute to Papain-Induced Innate-Type Air-
way Eosinophilia
(A) Cell numbers and concentrations of cytokines
in BALF and lungs from C57BL/6N wild-type mice
24 hr after the final inhalation of various doses of
papain (n = 5–6).
(B–D) Numbers of eosinophils and neutrophils in
BALF frommice24hr after papain inhalation (25mg)
(heat-inactivated papain [HI], n = 3–6; and papain,
n = 10–21).Wild-type and Il33/mice (B),Rag2/
mice injected with anti-mouse CD25 mAb and
control IgG (C), and wild-type, Rag2/ Il2rg/
mice, and Rag2/ Il2rg/ mice which had been
engrafted with NH cells from wild-type mice (D).
(E) Numbers of eosinophils and neutrophils in BALF
and expression of IL-33 mRNA in the lungs from
wild-type and Par2/ mice 24 hr after papain
inhalation (25 mg). Heat-inactivated papain [HI], n =
7–8 forBALF, andn=5 for IL-33mRNA;andpapain,
n = 20–21 for BALF, and n = 8 for IL-33 mRNA.
(F) IL-33 expression in lungs from C57BL/6N
wild-type mice after papain inhalation (25 mg). Red,
IL-33 staining; blue, DAPI staining. Scale bars
represent 100 mm. The data show themean ± SEM
(A) or mean + SEM (B–E). *p < 0.05, **p < 0.01, and
***p < 0.005 versus 0 mg papain (A) and HI (B–E);
yp < 0.05 and yyyp < 0.005 versus papain-treated
wild-typemice (B, D, E) and papain-treated control
IgG-injected Rag2/ mice (C); and yyp < 0.01
versus papain-treated Rag2/ Il2rg/ mice en-
grafted with NH cells (Rag2/ Il2rg/ + NH).Similarly, the plant-derived cysteine protease, papain, which
is homologous to HDM-derived Der p1 and human cathepsin B
(Chua et al., 1988), is known to induce airway inflammation in
humans and is a cause of occupational asthma (Milne and
Brand, 1975). In mice, we and others showed that papain can
induce production of an alarmin, interleukin-33 (IL-33), a mem-
ber of the IL-1 family of cytokines, by lung epithelial cells, fol-
lowed by induction of IL-5 and IL-13 production by lung natural
helper (NH) cells, resulting in development of IL-4 and IL-13-
STAT6-dependent eosinophilic airway inflammation even in
the absence of acquired immune cells such as T and B cells
(Halim et al., 2012; Oboki et al., 2010). Thus, it is thought
that pathogen- or plant-derived proteases, which are distinct
from pathogen-associated molecular patterns, can initiate
antigen-non-specific allergic inflammation via activation of the
innate immune system by causing release of alarmins such as
IL-33 from damaged epithelial cells (Kiss et al., 2007), which
is later followed by establishment of antigen-specific allergic re-176 Immunity 43, 175–186, July 21, 2015 ª2015 Elsevier Inc.sponses via activation of the adaptive
immunity (Sokol et al., 2008).
Like NH cells, mast cells (MCs) are
considered to be major effector cells in
certain allergic disorders and can secrete
a variety of inflammatory mediators in
response to IL-33 even in the absence
of immunoglobulin E (IgE) (Ho et al.,
2007; Iikura et al., 2007). Therefore, we
hypothesized that MCs can cooperatewith NH cells in enhancing protease and IL-33-induced innate-
type airway inflammation. However, in the present study, we
found that IL-33-stimulated MCs can play a suppressive role in
this setting by promoting an expansion of regulatory T (Treg)
cell numbers that is dependent on MC-derived IL-2. Thus,
MCs can negatively regulate the initiation phase of papain and
IL-33-induced innate-type airway inflammation.
RESULTS
NH Cells Contribute to Protease-Mediated Eosinophilia
Inhalation of papain by mice resulted in the dose-dependent
development of airway inflammation accompanied by accumula-
tion of macrophages, eosinophils, neutrophils, lymphocytes, and
natural helper (NH) cells in the bronchoalveolar lavage fluid
(BALF), increased numbers of NH cells and MCs in the lungs,
and increased concentration of IL-5 and IL-13, but not IL-4, in
the BALF (Figure 1A). Inhalation of a high dose of papain
(100mg), but not of a lower doseof papain (25 mg), resulted in hem-
orrhage associated with destruction of blood vessel walls, as well
as lungepithelial cells, presumably reflecting thestrongproteinase
activitiesofpapain (Kamijoetal., 2013). Indeed,high-dosepapain-
mediated airway inflammation is considered to be a model for
COPD (Chapman, 2008). The histology of lungs frommice treated
with 25 mg papain resembled that seen in asthma (in that eosino-
phils are prominent), whereas the lung pathology in mice treated
with 100 mg papain had features of COPD, including enlarged air-
spaces (Figure S1A). The pathology induced by 50 mg papain
showed an intermediate phenotype (Figure S1A). In association
with increases in the numbers of eosinophils in BALFs (Fig-
ure S1C), the expression of IL-33 mRNA in the lungs (Figure S1B),
the numbers ofMCs in the lungs (Figure S1C), and numbers of NH
cells in the BALFs and the lungs (Figure S1D) were significantly
increased 24 hr after the 1st or 2nd papain inhalation. Consistent
withprevious studies (Halimet al., 2012;Oboki et al., 2010), airway
eosinophilia, but not neutrophilia, was significantly attenuated
24 hr after the 3rd papain inhalation in Il33/ mice, in Rag2/
mice, which had been depleted of NH cells by injection of anti-
CD25 mAb, and in Rag2/ Il2rg/ mice, which lack NH cells as
well as T, B, NKT, and NK cells (Moro et al., 2010) (Figures 1B–
1D). As reported previously (Halim et al., 2012), the impaired
airway eosinophilia 24 hr after the 3rd papain inhalation that was
seen in Rag2/Il2rg/ mice was partially restored to that seen
in wild-type mice by injection of NH cells into Rag2/Il2rg/
mice (Figure 1D). In addition, papain-IL-33-NH-cell-mediated
airway eosinophilia and lung expression of IL-33mRNA24 hr after
the 3rd papain inhalation were also significantly, albeit partially,
suppressed in mice deficient in protease-activated receptor 2
(Par2) (Figure 1E). Immunoreactive IL-33 protein was detected in
the nuclei of alveolar epithelial cells from wild-type mice, but not
Il33/ mice, 24 hr after the 3rd inhalation of papain, but not after
inhalation of heat-inactivated papain (Figure 1F). This suggests
that IL-33 released from alveolar epithelial cells by papain, at least
in part throughPar2, activates lungNHcells, followedby induction
of airway eosinophilia (hereinafter called papain-IL-33-NH-cell-
mediated airway eosinophilia).
MCs Suppress NH Cell-Mediated Eosinophilia
Because IL-33 induces mast cells (MCs) to secrete Th2 type-cy-
tokines (Ho et al., 2007; Iikura et al., 2007), MCs are thought to
cooperatewithNHcells in enhancingprotease or IL-33-mediated
innate-type airway eosinophilia. Unexpectedly, MC-deficient
KitW-sh/W-sh mice exhibited exacerbated papain-IL-33-NH-cell-
mediated airway eosinophilia in comparison with wild-type mice
after inhalation of low-dose papain (Figure 2A). In contrast, the re-
sponses in the two groups were not significantly different when
the mice were treated with high-dose papain, which induced
strong responses in all groups (Figure S2A). Likewise, papain-
IL-33-NH-cell-mediated airway eosinophilia was exacerbated in
Rag2/ mice compared with wild-type mice after inhalation of
low-dose papain (Figure 2B), but not in the strong reactions that
occurred after inhalation of high-dose papain (Figure S2A). In
accord with these findings, the amounts of IL-5 and IL-13, but
not IL-4, in the BALF and airway inflammation were increased in
KitW-sh/W-sh mice and Rag2/ mice compared with wild-type
mice after inhalation of low-dose papain (Figures 2A and 2B; Fig-
ures S2A–S2C). In addition, NH cells in the BALF and the lungs ofKitW-sh/W-sh mice and Rag2/ mice and MCs in the lungs of
Rag2/micewere significantly increased in numbers compared
with wild-type mice after inhalation of low-dose papain (Fig-
ure 2C), although the proportion of IL-5+ IL-13+ NH cells in the
BALFsand that of IL-2+ c-Kit+ FcεRIa+MCs in the lungswascom-
parable in KitW-sh/W-sh mice, Rag2/ mice and wild-type mice
(Figure S2D), and in Rag2/ mice and wild-type mice (Fig-
ure S2E), respectively. Similarly, inKitW-sh/W-sh mice andRag2/
mice, airway inflammation (as assessed by eosinophil numbers,
amounts of IL-5 and IL-13 in BALF, or lung histology) was ex-
acerbated versus amounts in wild-type mice after inhalation of
low-dose IL-33 (Figure 2D; Figures S2F andS2G), but such differ-
ences were not observed in the strong responses that occurred
after inhalation of high-dose IL-33 (Figure S2H). In certain mouse
disease models, different results have been reported regarding
the role of MCs based on studies in Kit mutant MC-deficient
mice (suchasKitW/W-v andKitW-sh/W-shmice) versusMC-depleted
mice which lack abnormalities in c-Kit (Reber et al., 2012; Rode-
wald and Feyerabend, 2012). In the present model system, we
confirmed that the exacerbated airway eosinophilia induced by
low-dose IL-33 was also observed in MC-depleted Mas-TRECK
mice (Figure S2I).
We also found that the amounts of IL-5 and IL-13 in the BALF
from papain-treated mice were substantially lower than those
from IL-33-treated mice (Figures 2A, 2B, and 2D), perhaps
because these cytokines, which contain cysteine residues, can
be directly degraded by papain (Figure S2J).
Taken together, these observations suggest that MCs and
rag-dependent immune cells suppress airway eosinophilia
induced by optimal doses of papain or IL-33.
Treg Cells Can Suppress NH Cell-Mediated Eosinophilia
The above observations suggest that MCs and Rag-dependent
immune cells such as T, B, and/or NKT cells can play regulatory
roles in airway eosinophilia induced by certain doses of papain
and IL-33. Lymphocytes were very sparse in BALF from saline-
treated wild-type mice, but significantly increased in number in
BALF from papain-challenged wild-type mice (Figure 1A). After
inhalation of papain or IL-33, the proportion and number of
CD25+Foxp3+ Treg cells in CD4+ T cells in BALF from wild-type
mice increased (Figure 3A). In accord with this, the proportion
and/or numberof Tregcellswassignificantly increased in thoracic
LNs, but not the spleen, from papain- or IL-33-treated wild-type
mice compared with naive wild-type mice (Figure 3A). Like IL-5
and IL-13 (Figure S2J), IL-33 also can be degraded by papain
(data not shown). Indeed, we could not detect IL-33 in the BALF
ofwild-typemice after papain inhalation (data not shown), despite
the ability of papain to induce increased expression of IL-33 in the
nuclei of airway epithelial cells (Figure 1F), perhaps because
papain-induced IL-33 was degraded by papain. Therefore, the
amounts of IL-33 in the BALF of papain-treated mice were sub-
stantially lower than those in the BALF of IL-33-treated mice,
and this was associated with different numbers of Treg cells in
papain- and IL-33-treated mice. In addition, when lymphocytes
were cultured with papain, heat-inactivated papain, or IL-33,
papain, but not heat-inactivated papain or IL-33, induced cell
death (data not shown). Such effects of papain might account
for why numbers of Treg cells in the BALF, but not in LNs, might
be smaller in papain-treated mice than in IL33-treated mice.Immunity 43, 175–186, July 21, 2015 ª2015 Elsevier Inc. 177
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Figure 2. Exacerbated Papain-IL-33-NH-
Cell-Mediated Airway Eosinophilia in
Rag2-Deficient and Mast-Cell-Deficient
KitW-sh/W-sh Mice
(A and B) Numbers of eosinophils and levels of
IL-4, IL-5, and IL-13 in BALF from wild-type mice
and KitW-sh/W-sh mice (heat-inactivated papain [HI],
n = 5; and papain; n = 24–25) (A) and wild-type
mice and Rag2/ mice (heat-inactivated papain
[HI], n = 5; and papain; n = 10–25). (B) 24 hr after
the final inhalation of low-dose papain (25 mg).
(C) Numbers of NH cells and MCs in BALF and/or
lungs from wild-type mice, KitW-sh/W-sh mice, and
Rag2/mice 24 hr after the final inhalation of low-
dose papain (25 mg) (heat-inactivated papain [HI],
n = 5–10; and papain; n = 5–10).
(D) Numbers of eosinophils and levels of IL-4, IL-5,
and IL-13 in BALF fromwild-typemice,KitW-sh/W-sh
mice, and Rag2/ mice 24 hr after the final inha-
lation of low-dose IL-33 (0.1 mg) (saline, n = 4–6;
and IL-33, n = 11–15). The data show the mean +
SEM. *p < 0.05 and ***p < 0.005 versus HI (A–C)
and saline (D), and yp < 0.05 and yyyp < 0.005
versus papain-treated wild-type mice (A–C) and
IL-33-treated wild-type mice (D).The exacerbated airway eosinophilia seen in Rag2/ mice
after papain or IL-33 inhalation was attenuated in Rag2/
mice after transfer of Treg cells to produce numbers similar to
those seen in wild-type mice (Figure 3B). These observations
suggest that Treg cells are crucial for regulation of papain-IL-
33-NH-cell-mediated innate-type airway eosinophilia, while
effector T cells are not. In support of this conclusion, the
reduced proportion of Treg cells in thoracic LNs after papain
or IL-33 inhalation also correlated inversely with the exacer-
bated airway eosinophilia in KitW-sh/W-sh mice or Mas-TRECK
mice compared with wild-type mice (Figures 3C–3E; Figure S3).
Nevertheless, the proportion of Treg cells in thoracic LNs was
comparable between saline-treated wild-type and KitW-sh/W-sh
mice or Mas-TRECK mice (Figures 3D and 3E; Figure S3). Injec-
tion of Treg cells into KitW-sh/W-sh mice resulted in the same178 Immunity 43, 175–186, July 21, 2015 ª2015 Elsevier Inc.attenuating effect as noted above for
Rag2/ mice (Figure 3F). Thus, MCs
can influence expansion of numbers of
Treg cells during papain-IL-33-NH-cell-
mediated airway eosinophilia.
MastCells Induce TregCell Number
Expansion
We observed close associations between
mast cells and Treg cells in the lungs of
mice after papain inhalation (Figure S4A).
To investigate whether MCs might
directly influence Treg cell differentiation
in mice, we co-cultured mouse CD4+
CD25CD62L+ naive splenic T cells
with wild-type mouse bone-marrow-cell-
derived cultured MCs (BMCMCs) in the
presence or absence of IL-33. The pro-
portion of CD4+CD25+Foxp3+ Treg cellswas increased in the co-cultures in the presence of IL-33 (Fig-
ure 4A). Compared to results obtained with naive T cells, a
more substantial expansion of CD4+CD25+Foxp3+ Treg cell
numbers was observed in co-cultures of whole splenic CD4+
T cells (that included resident Treg cells) andwild-type BMCMCs
compared with culture of whole splenic CD4+ T cells alone,
even without any exogenous immunostimulant (i.e., in medium
alone: 1.9%; Figure 4B). Moreover, addition of IL-33 to such
MC-whole CD4+ T cell co-cultures, but not to whole CD4+
T cell cultures that lacked MCs, markedly expanded the popula-
tion of CD4+CD25+Foxp3+ Treg cells (Figures 4B and 4D). We
also found that the FoxP3+ Treg cells, which expanded in the
co-cultures, expressed the transcription factor Helios (Fig-
ure 4B). When CD4+ CD25+ T cells enriched from the spleen
were co-cultured with wild-type BMCMCs in the presence of
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Figure 3. Evidence that Treg Cells and
Mast Cells Are Necessary for Suppression
of Papain-IL-33-NH-Cell-Mediated Airway
Eosinophilia
(A) Proportions of CD4+CD25+Foxp3+ Treg cells
in BALF, thoracic LNs and spleen from naive,
papain-inhaled and/or IL-33-inhaled C57BL/6J
wild-type mice. Since the number of lymphocytes
in BALF from naive mice was so small, the
proportion of CD4+CD25+Foxp3+ Treg cells in
these mice was hardly detectable. Data show
representative results from three independent
experiments.
(B) Numbers of eosinophils in BALF from wild-type
mice, Rag2/mice, and Rag2/mice which had
been engrafted with CD4+CD25+ Treg cells from
spleens of wild-type mice (Rag2/ + Treg) 24 hr
after the final inhalation of 25 mg of papain or 0.1 mg
of IL-33 (heat-inactivated papain [HI], n = 4–5;
versus papain, n = 16; and saline, n = 5, versus IL-
33, n = 13).
(C–E) Numbers of eosinophils in BALF (C), and
(D and E) proportions of CD4+CD25+Foxp3+
Treg cells in thoracic LNs from wild-type mice and
KitW-sh/W-sh mice 24 hr after the final inhalation of
25 mg of papain or 0.1 mg of IL-33 (saline, n = 9;
papain, n = 10; and IL-33, n = 10). FACS data show
representative results in (D).
(F) Numbers of eosinophils in BALF from wild-type
mice, KitW-sh/W-sh mice, and KitW-sh/W-sh mice
that had been engrafted with CD4+CD25+ Treg
cells from spleens of C57BL/6J wild-type mice
(KitW-sh/W-sh + Treg) 24 hr after the final inhalation of
25 mg of papain or 0.1 mg of IL-33. Data show the
mean +SEM (HI, n = 4–5, versus papain, n = 10–15;
saline, n = 5, versus IL-33, n = 13). *p < 0.05 and
***p < 0.005 versus HI or saline (B, C, and F), and
yp < 0.05 and yyp < 0.001 versus papain-treated or
IL-33-treated wild-type mice (B, C, and F) and
versus papain-treated or IL-33-treated Rag2/ +
Treg groups orKitW-sh/W-sh + Treg groups (B and F).IL-33, CD4+CD25+Foxp3+ Treg cells were significantly ex-
panded (Figure 4C). These in vitro results are consistent with
the conclusion that IL-33-stimulated BMCMCs increase num-
bers of Treg cells primarily via expansion of numbers of
committed Tregs, but might also induce some de novo Treg
cell differentiation.
BMCMCs derived from mice deficient in IL-1RL1 (also called
ST2) and MyD88, which are components of the IL-33 receptor
and IL-33 signaling, respectively, failed to enhance Treg cell
expansion upon stimulation with IL-33 (Figure 4D). IL-33 can
stimulate MCs to secrete IL-6 (Figure S4C), which is a key cyto-
kine for Th17-cell differentiation. In contrast, we detected no
significant effect of MC-derived IL-6 on IL-33-mediated expan-
sion of Treg cell number; nor did MCs expand Th17 or Th2
cell numbers (Figure 4D; Figure S4D), probably because we
did not use any TCR-mediated stimuli such as anti-CD3 mAb
in the MC-whole CD4+ T cell co-cultures. In support of thisImmunity 43, 175–conclusion, MHC class II (H2-Ab1)-defi-
cient BMCMCs efficiently induced IL-33-
mediated Treg cell expansion in MC-
whole CD4+ T cell co-cultures (Figure 4E).In addition, Treg cell expansion in number in those co-cultures
was not induced by LPS or IL-1b (Figure S4E), or by IgE (Figures
S4E and S4G), IL-13, IL-25, or TSLP (Figure S4F), even though
the signal transduction pathway involving LPS and IL-1b via
TLR4 and IL-1R, respectively, is shared by IL-33 via IL-33R.
We also found that IL-33 enhanced CD4+CD25+Foxp3+ Treg
cell number expansion from human peripheral blood-derived
CD4+ T cells in the presence, but not absence, of peripheral
blood stem-cell-derived cultured humanMCs in vitro (Figure 4F).
We observed that the effect of IL-33 in human cells was less than
that in mouse cells, perhaps because of the smaller number of
Treg cells in CD4+ T cells isolated from human peripheral blood
compared to those from mouse spleens.
Next, to assess whether in vitro-expanded Treg cells can sup-
press airway inflammation in vivo, we administered IL-33 intra-
nasally (i.n.) immediately after injecting KitW-sh/W-sh mice with
CD4+CD25+ Treg cells derived from co-culture of CD4+ T cells186, July 21, 2015 ª2015 Elsevier Inc. 179
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Figure 4. IL-33-Stimulated Mast Cells Can
Enhance Treg Cell Expansion In Vitro
(A–F) Mouse (A–E) or human (F) CD4+ T cells were
cultured with and/or without mouse bone-marrow-
derived cultured mast cells (MCs) (A–E) or human
peripheral blood stem-cell-derived cultured MCs (F)
in the presence and absence of IL-33 for 3 days. The
proportions and numbers of CD25+Foxp3+ and/or
Helios+ Treg cells among c-Kit-negative CD4+ T cells
were assessed by flow cytometry. Data show
representative results from 3–5 batches of MCs per
experiment and from 2–3 independent experiments,
each of which gave similar results (A, B, D–F). (A) Co-
culture of mouse CD4+CD25CD62L+ naive T cells
and wild-type MCs. (B) Proportion of CD25+Foxp3+
Treg cells, and expression of Helios in CD4+ CD25+
T cells in co-culture of mouse CD4+ T cells (not naive
T cells) and wild-type MCs in the presence of IL-33.
(C) Co-culture of mouse CD4+CD25 + Treg cells and
wild-type MCs. After flow cytometric analysis, the
number of Treg cells was calculated. Data show the
mean + SEM (n = 3). (D) Culture of mouse splenic
CD4+ T cells with and without wild-type, Myd88/,
Il1rl1/, or Il6/ MCs. (E) Co-culture of mouse
CD4+ T cells with wild-type or H2-Ab1/ MCs. (F)
Co-culture of human peripheral blood-derived CD4+
T cells with and without human peripheral blood
stem-cell-derived cultured MCs.and wild-type BMCMCs in the presence of IL-33. Eosinophil
counts in the BALF were significantly decreased in KitW-sh/W-sh
mice that had been engrafted with wild-type, but not Il10/,
CD4+CD25+ Treg cells (Figure 5A). These results suggest that
the ability to secrete IL-10 is essential for the immunoregulatory
function of the CD4+CD25+ Treg cells that expanded in response
to IL-33-mediated MC activation in vitro.
Microarray analysis indicates that mouse NH cells express IL-
10R1mRNA (Moro et al., 2010). NH cells in BALF from papain- or
IL-33-treated wild-type mice expressed IL-10R1 (Figure 5B).
Moreover, proliferation by NH cells in response to IL-33, but
not to IL-2, IL-25, or IL-2 + IL-25, was significantly inhibited by
the addition of 0.5-50 ng/ml IL-10 (Figure 5C) or 10 ng/ml IL-10
(Figure 5D). In association with the inhibition of NH cell prolifera-
tion by IL-10, the amounts of IL-5 and IL-13 in the culture super-
natants were also reduced in this setting (Figures 5C and 5D). In180 Immunity 43, 175–186, July 21, 2015 ª2015 Elsevier Inc.addition, we found that IL-10R1 mRNA also
was expressed in human ILC2 (Figure 5E).
Proliferation and IL-13 production by hu-
man ILC2s in response to IL-33 plus IL-2
was significantly suppressed when human
ILC2s were co-cultured with human Treg
cells (Figure 5F). These observations sug-
gest that Treg cell-derived IL-10 may regu-
late NH cell function directly.
MC-Derived IL-2 in Treg Cell Number
Expansion
MC-derived soluble factors and co-stimu-
latory molecules each can be important
for MC-dependent T cell activation (Ka-
shiwakura et al., 2004; Nakae et al.,2005). We found that IL-33- and BMCMC-mediated Treg cell
number expansion was largely, but not completely, inhibited
by using a transmembrane filter to separate whole CD4+
T cells and BMCMCs (Figure 6A), suggesting that both solu-
ble molecules and cell-cell proximity (perhaps because this
allows engagement of membrane-associated molecules) are
required for full induction of Treg cells. In addition to IL-6,
IL-13, and TNF (Figure S4C), we found that IL-33 stimulation
induced BMCMCs to produce TGF-b1 and IL-2 (Figure S5A),
which are critical for Treg cell development and expansion
in number, respectively (Josefowicz et al., 2012), but not
IL-10 (Figure S5A). Similarly, MCs purified from lungs pro-
duced IL-2 in response to 10 ng/ml IL-33 in vitro (20 ng/ml
versus 273 ng/ml after medium versus IL-33 stimulation).
Notably, Il2/ BMCMCs, in contrast to Tgfb1/ or Il10/
BMCMCs, failed to expand Treg cells in MC-whole CD4+
A B
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Figure 5. Suppression of Airway Eosino-
philia by Treg Cells Derived from IL-33-Stim-
ulated MCs
(A) Numbers of eosinophils in BALF from wild-type
mice, KitW-sh/W-sh mice and KitW-sh/W-sh mice en-
grafted with IL-33- and MC-derived wild-type
CD4+CD25+ Treg cells (KitW-sh/W-sh + WT Treg) or
Il10/CD4+CD25+ Treg cells (KitW-sh/W-sh + Il10/
Treg) at 24 hr after the final IL-33 or saline inhalation.
Data show themean + SEM (saline, n = 5; and IL-33,
n = 10). ***p < 0.005 versus saline, and yp < 0.001
versus values from wild-type or KitW-sh/W-sh + WT
Treg groups.
(B) Expression of IL-10R1 on NH cells from BALF of
C57BL/6J-wild-type mice after the final inhalation
of 25 mg of papain or 0.1 mg of IL-33. BAL cells
were incubated with anti-IL-10R1 mAb or isotype
matched control IgG in the presence and/or
absence of rmIL-10. The expression of IL-10R1 on
NH cells (gated by NH cell markers) in BAL cells was
determined by flow cytometry. Gray lines = isotype-
matchedcontrol IgGstaining, red lines=anti-mouse
IL-10R1 mAb staining or a green line = anti-mouse
IL-10R1 mAb staining in the presence of rmIL-10.
Since the proportion of lymphocytes in BALF from
naivemicewas very small, theproportionofNHcells
in these mice was hardly detectable. Data show
representative results from one of three mice.
(C) Numbers of NH cells and percent inhibition of
numbers of NH cells, and IL-5 and IL-13 production
by NH cells, in response to 10 ng/ml IL-33 in the
presence and absence of 0.5 2 and 50 ng/ml IL-10.
Data show the mean + SD (n = 3). *p < 0.05 versus
0 (no added IL-10).
(D) Numbers of NH cells, and IL-5 and IL-13 pro-
duction by NH cells, in response to 10 ng/ml IL-2,
10ng/ml IL-25,10ng/ml IL-33, and IL-2+ IL-25 in the
presence and absence of 10 ng/ml IL-10.Data show
the mean + SD (n = 3) *p < 0.05 versus Medium.
(E) Expression levels of IL-10R1 mRNA in human
ILC2s, Jurkat cells and HeLa cells were determined
by quantitative PCR.Data showmean +SEM (n = 3).
(F) Human ILC2s were co-cultured with and without
human Treg cells in the presence of 50 ng/ml IL-33
and 10 U/ml IL-2. Data show representative results
from the two independent experiments performed,
each of which gave similar results.T cell co-cultures in the presence of IL-33 (Figures 6B–6D).
Indeed, IL-2 production was also detected by immunohisto-
chemistry in lung mast cells from papain- or IL-33-treated
wild-type, but not Il2/ or Il1rl1/, mice (Figures S5B–S5E).
Moreover, addition of neutralizing mAbs for IL-2, ICAM-1,
CD86, or 4-1BBL, but not PD-L1, ICOSL, OX40L, CD80, or
FasL, significantly decreased Treg cell expansion (Figure 6E).
Thus, the co-stimulatory and adhesion molecules ICAM-1,
CD86, and 4-1BBL and especially MC-derived IL-2 contribute
to the Treg cell expansion in numbers observed in this system.
Next, to investigate the role of IL-2 produced by MCs in vivo,
we administered IL-33 intranasally to KitW-sh/W-sh mice engrafted
with wild-type or Il2/ BMCMCs. In wild-type BMCMC-en-
grafted mice, the numbers of eosinophils were reduced to the
levels observed in wild-type mice after IL-33 inhalation (Fig-
ure 7A). In contrast, engraftment with Il2/ BMCMCs did notresult in normalization of the exacerbated response to intranasal
IL-33, and neither did engraftment with Il1rl1/ BMCMCs (Fig-
ure 7A). In agreement with this, the decrease in the proportion
of Treg cells in thoracic LNs of KitW-sh/W-sh mice after IL-33 inha-
lation was reversed by engraftment of the mice with wild-type,
but not Il2/ or Il1rl1/, BMCMCs (Figures 7B and 7C). Similar
results were observed in these mice after papain inhalation (Fig-
ure 7D). When wild-type BMCMCs were co-cultured with lung
epithelial cells (ECs) from wild-type or Il33/ mice in the pres-
ence of papain or heat-inactivated papain, wild-type BMCMCs
co-cultured with wild-type ECs, but not with Il33/ ECs, pro-
duced IL-2 after papain stimulation (Figure 7E). These observa-
tions suggest that IL-33, induced by papain, stimulates MCs
via IL-1RL1 to produce IL-2, which can in turn suppress
papain/IL-33/NH-cell-mediated airway eosinophilia by promot-
ing Treg-cell expansion in numbers.Immunity 43, 175–186, July 21, 2015 ª2015 Elsevier Inc. 181
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Figure 6. Importance of MC-Derived IL-2 and
Costimulatory Molecules for IL-33- and MC-
Mediated Treg Cell Expansion In Vitro
(A–E) Mouse CD4+ T cells (not naive T cells) were
cultured with and/or without mouse bone-marrow-
derived cultured MCs (MCs) in the presence and
absence of IL-33 for 3 days. The proportion of
CD25+Foxp3+ Treg cells among c-Kit-negative
CD4+ T cells was assessed by flow cytometry. (A)
Co-culture of CD4+ T cells with wild-type MCs
separated by transmembrane filters (Separated) or
cultured together (Not separated). (B) Co-culture of
CD4+ T cells with wild-type or Il2/ MCs in the
presence and absence of IL-33. (C) Co-culture of
CD4+ T cells with Tgfb1+/+ or Tgfb1/ MCs in the
presence and absence of IL-33. (D) Co-culture of
CD4+ T cells with wild-type or Il10/ MCs in the
presence and absence of IL-33. (E) Co-culture of
CD4+ T cells with wild-type MCs in the presence of
neutralizing mAb for adhesion/co-signaling mole-
cules. (A–D) Data show representative results from
3–5 batches of MCs per experiment and from the
2–3 independent experiments performed, each of
which gave similar results. (E) Data show the mean +
SEM (n = 5). **p < 0.01 versus control IgG groups.DISCUSSION
It is now well established that IL-33 can induce Th2 cell-type
inflammation accompanied by eosinophils, i.e., IL-33 can have
pro-inflammatory effects (Chackerian et al., 2007; Kondo et al.,
2008; Kurowska-Stolarska et al., 2008; Schmitz et al., 2005; Xu
et al., 2008). Although IL-33 also can attenuate cardiomyocyte
hypertrophy and cardiac fibrosis after pressure overload (San-
ada et al., 2007), the molecular mechanisms accounting for
these effects of IL-33 are not fully understood. In the present
study, we provide additional evidence that the plant-derived pro-
tease papain, which activates innate immune responses in a
manner distinct from that of pathogen-associated molecular
patterns such as LPS, can induce secretion of an alarmin, IL-182 Immunity 43, 175–186, July 21, 2015 ª2015 Elsevier Inc.33, by lung epithelial cells to induce NH-
cell-mediated acute allergic inflammation
in the lungs of naive mice, and showed
that this effect of papain on lung epithelial
cells is in part dependent on Par2.
We found that IL-33 protein was barely
detectable in lung epithelial cells from
heat-inactivated papain-treated wild-type
mice. By contrast, high amounts of IL-33
protein expression were observed in lung
epithelial cells of naive and PBS-treated
IL-33-reporter mice (Pichery et al., 2012).
In contrast, constitutive IL-33 protein
expression was detected in airway epithe-
lial cells from PBS-treated IL-33-reporter
mice, although the levels of IL-33 protein
expression were lower in these cells and
the frequency of IL-33-positive cells was
much lower in lungs from PBS-treated IL-
33-reporter mice than antigen-challengedIL-33-reporter mice (Hardman et al., 2013). We do not know
the reason for the differences among our results and those of
Pichery et al. and Hardman et al. and can only speculate that
they might reflect differences in the animals’ housing conditions
(i.e., under SPF conditions or conventional conditions) and/or
other factors that remain to be defined.
Although IgE-stimulated mast cells are well known to have
potent effector cell functions in the pathology of allergic
disorders, we have provided multiple lines of evidence that
IL-33-stimulated mast cells can play a regulatory role in the
development of NH-cell-mediated non-antigen-specific prote-
ase-induced acute inflammation. Our evidence indicates that
MCs can do this by producing IL-2 that in turn enhances Treg
cell expansion in naive mice that lack antigen-specific IgE. IgE
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Figure 7. Importance of IL-2 Produced by
IL-33-Stimulated Mast Cells for Suppres-
sion of Papain-IL-33-NH-Cell-Mediated Air-
way Eosinophilia
(A–D) Mice were intranasally administered 0.1 mg IL-
33 or saline, or 25 mg papain or heat-inactivated
papain (HI) for 3 days (once per day). Numbers of
eosinophils in BALF and proportions of Foxp3+ Treg
cells among CD4+ cells in thoracic LNs from wild-
type mice, KitW-sh/W-sh mice and KitW-sh/W-sh mice
that had been engraftedwith wild-type (WT), Il2/, or
Il1rl1/ MCs before the start of IL-33 or saline
challenge) at 24 hr after the final IL-33 or saline
inhalation (saline, n = 5; IL-33, n = 10) (A–C) or at 24 hr
after the final papain or heat-inactivated papain (HI)
inhalation (HI, n = 4–6; papain, n = 10–11) (D). Data
show themean +SEM (A, C, andD). *p < 0.005 versus
saline or HI and yp < 0.05 versus wild-type mice or
KitW-sh/W-sh mice that had been engrafted with wild-
typeMCs (KitW-sh/W-sh +WTMCs). FACS data show a
representative result in each IL-33-treated group, as
shown in (C).
(E) IL-2 production by wild-type MCs co-cultured
with or without lung epithelial cells (ECs) from wild-
type (WT) or Il33/ mice in the presence of papain
and monensin for 6 hr. Green, IL-2; Red, MC; and
Blue, Hoechst. Scale bars represent 10 mm. Repre-
sentative results in each group are shown. No stain-
ing was obtained with the isoptype control for the
anti-IL-2 Ab (data not shown).and specific Ag, but not IL-33, can induce degranulation of MCs
(Ho et al., 2007; Iikura et al., 2007). By contrast, we found that IL-
33-stimulated MCs, but not IgE and Ag-stimulated MCs, can
induce Treg cell expansion. Moreover, IgE and Ag-stimulated
mast cells and Treg cells can suppress each other’s function in
the setting of anaphylaxis (Gri et al., 2008; Piconese et al.,
2009). Thus, MCs appear to play distinctly different, indeed
opposite, roles in the induction of the acute phase of papain-
induced innate allergic inflammation in naive mice (in which
MCs downregulate the response) and in antigen-sensitized
mice bearing antigen-specific-IgE (in which MCs have a major
role in initiating and amplifying the response).
MCs can negatively regulate innate or adaptive immune re-
sponses in mice. For example, MCs have been reported to pro-Immunity 43, 17mote peripheral tolerance to skin allografts
(Lu et al., 2006). In contrast to wild-type
mice, MC-deficient KitW-sh/W-sh mice that
received donor-specific transfusion and
anti-CD154 Ab treatment to induce toler-
ance exhibited significantly impaired sur-
vival of allogenic skin grafts (Lu et al.,
2006). It was proposed that Treg-cell-
derived IL-9 inducedMCactivation in the al-
lografts, and that MC activation, and
perhaps IL-10, contributed to the effective-
ness of Treg-cell-mediated allograft toler-
ance (Lu et al., 2006). These findings are
consistent with the interpretation that
MCs function downstream of Treg cells in
enhancing tolerance to skin allografts, butthe exact relationship between mast cells and Treg cells in this
model remains to be determined. In other settings, MCs have
been reported to exert anti-inflammatory or immunosuppressive
effects via the production of histamine (Hart et al., 1998) or by un-
known mechanisms (Depinay et al., 2006). It has also been re-
ported that IgG-stimulated MC-derived IL-10 or IgE-stimulated
MC-derived IL-2 can have effects that suppress the chronic
phase of local inflammation in certain models of contact hyper-
sensitivity (Grimbaldeston et al., 2007; Hershko et al., 2011).
Finally, after hematopoietic cell transplantation, graft versus
host disease (GVHD) was severely exacerbated in C57BL/6-
KitW-sh/W-sh mice (median survival time, MST = 13 days versus
60 days in WT mice; p < 0.0001) (Leveson-Gower et al., 2013).
However, the survival of C57BL/6-KitW-sh/W-sh mice during5–186, July 21, 2015 ª2015 Elsevier Inc. 183
GVHD was significantly improved if the mice were engrafted
intraperitoneally (i.p.) with BMCMCs from WT C57BL/6 mice
but not from IL-10-deficient C57BL/6mice. These data and other
findings in that study (e.g., showing that Treg cell numbers and
function were similar in the C57BL/6-KitW-sh/W-sh and wild-type
mice) indicate that the presence of mast cells can significantly
reduce GVHD pathology in C57BL/6-KitW-sh/W-sh mice indepen-
dently of Treg, by decreasing proliferation of conventional T cells
by a mechanism involving IL-10. The present study identifies
another mechanism of MC-dependent negative regulation of
inflammation, in which IL-33-activated MCs function upstream
of Treg cells, and independently of antigen-specific IgE, in
enhancing Treg-dependent downregulation of the acute phase
of papain-IL-33-NH-cell-mediated airway inflammation.
Can mast cells exhibit such a function in humans, as well as in
mice? Although evaluating this question in humans in vivo is diffi-
cult, we have addressed it by analyzing co-cultures of peripheral
blood progenitor-cell-derived cultured human MCs and human
peripheral blood-derived CD4+ T cells. We found that IL-33
can enhance polyclonal expansion of CD4+CD25+Foxp3+ Treg
cells in co-cultures of human MCs and human T cells in vitro,
but that IL-33 had little or no effect in the absence of MCs. While
the clinical relevance of these findings is not yet clear, our data
indicate that co-culturing MCs and T cells in the presence of
IL-33 represents an approach for efficiently generating large
numbers of CD4+CD25+Foxp3+ Treg cells in vitro.
Taken together, our findings suggest that IL-33 and MCs can
play an anti-inflammatory or immunosuppressive negative-feed-
back role based on a pathway comprising IL-33-stimulated
induction of MC-derived IL-2 leading to expansion of IL-10-pro-
ducing CD4+CD25+Foxp3+ regulatory T cells (by a mechanism
that is enhanced by mast cell-T cell proximity). The Treg cells
can then downregulate tissue inflammation.
EXPERIMENTAL PROCEDURES
Mice
C57BL/6J and C57BL/6N wild-type (Japan SLC), C57BL/6N-Il33/ (Oboki
et al., 2010), C57BL/6J-Mas-TRECK (Otsuka et al., 2011), C57BL/6-Rag2/,
C57BL/6-Rag2/ Il2rg/, C57BL/6-Il6/, C57BL/6-Il10/, C57BL/6-
Par2/ and 129 3 B6-Tgfb1+/, C57BL/6-KitW-sh/W-sh, C57BL/6-Myd88/,
C57BL/6-MHC class II (H2-Ab1)/, C57BL/6-Il2/, C57BL/6-Foxp3-GFP,
and C57BL/6-Il1rl1/ mice were used. All experiments were conducted in
accordance with the institutional ethical guidelines for animal experiments
and safety guidelines for gene manipulation.
Papain- and IL-33-Mediated Airway Inflammation
Mice were treated with papain (Calbiochem; 25 mg as a low-dose protocol and
50–100 mg as a high-dose protocol) or recombinant human IL-33 (rhIL-33: Pe-
proTech; 0.1 mg as a low-dose protocol and 5 mg as a high-dose protocol) in
20 ml of sterile, pyrogen-free 0.9%NaCl (‘‘saline’’) i.n. for 3 days (one inhalation
per day) unless otherwise specified. As controls, mice were treated with an
equal volume of heat-inactivated papain or saline alone.
Bronchoalveolar Lavage Fluid
Bronchoalveolar lavage fluid (BALF) was collected from naive mice or mice
24 hr after the last challenge with papain or IL-33, as described elsewhere
(Oboki et al., 2010).
Detection, Isolation, Culture, and Transfer of Mouse NH Cells
BALFwas collected at 24 hr after the last inhalation of papain, heat-inactivated
papain or saline. IL-1RL1+ CD25+ NH cells in 7-aminoactinomycin D Lin184 Immunity 43, 175–186, July 21, 2015 ª2015 Elsevier Inc.Sca1+ CD127+ cells and IL-10R1 expression in Lin CD90.1+ Sca-1 IL-
1RL1+ CD25+ NH cells were analyzed on a FACS Canto II (BD Bioscience).
NH cells were isolated as described previously (Moro et al., 2010) with mi-
nor modifications. For transfer of NH cells into Rag2/ Il2rg/ mice, freshly
isolated NH cells were cultured in the presence of 10 ng/ml rmIL-2 at 37C
for 1–2 months (Furusawa et al., 2013). The expanded NH cells (4 3 106
cells/mouse) were then intravenously injected into Rag2/ Il2rg/ mice.
One day after injection, the mice were intranasally treated with papain as
described above.
NH cells (5,000 cells/well in a 96-well round-bottom plate) were cultured in
the presence and absence of 10 ng/ml rmIL-33, rmIL-25, and rmIL-2, with
and without 10 ng/ml IL-10, at 37C for 5 days. The concentrations of IL-5
and IL-13 in the culture supernatants were measured by ELISA.
Mouse Mast Cell–T Cell Co-culture
T cells (1 3 106 cells/well [including approx. 5%–10% CD4+ CD25+ Treg
cells] in a 24-well plate) purified as described above were co-cultured for
3 days with BMCMCs (5 3 105 cells/well) in the presence and absence of
100 ng/ml rhIL-33 (PeproTech and R&D Systems). To separate MCs and
T cells, we used a Cell Culture Insert (0.4 mm pore size: BD Falcon) with
CD4+ T cells placed in the lower wells and BMCMCs placed in the upper
wells in the presence and absence of rmIL-33 for 3 days. Foxp3 and Helios
expression in c-Kit-negative CD4+CD25+ T cells, and IL-4, IL-13, and IL-17
expression in c-Kit-negative CD4+ T cells, were analyzed on a FACSCalibur
(Becton Dickinson), FACS Canto II (Becton Dickinson), or MACSQuant (Mil-
tenyi Biotech).
Human Mast Cell–T Cell Co-culture
Human cells were collected with the approval of the Ethical Review Board of
the National Research Institute for Child Health & Development in Japan.
The CD4+ T cells (2 3 106 cells; containing approx. 1%–2% of CD4+ CD25+
Treg cells) were co-cultured with and without peripheral blood-derived
cultured mast cells (5 3 105 cells) in the presence and absence of 100 ng/ml
rhIL-33 for 4 days. The co-cultures of T cells andmast cells used cells obtained
from the same donor. Foxp3 expression in CD4+CD25+ T cells was analyzed
by FACSCalibur.
Human ILC2-Treg Cell Co-culture
Human ILC2 were prepared as described previously (Mjo¨sberg et al., 2012),
with minor modifications. CD4+ CD25high CD127dim/ Treg cells were enriched
from PBMCs of healthy donors using a human CD4+ CD25+ CD127dim/ regu-
latory T cell Isolation Kit II (Miltenyi Biotec) according to the manufacturer’s in-
structions and then sorted on a FACS Aria.
ILC2 (1 3 104 cells/well) in 96-well round-bottom plates were co-cultured
with different numbers of autologous Treg cells in the presence of 10 U/ml
rhIL-2 and 50 ng/ml rhIL-33 at 37C for 3 days. After 3 days, the cells were
harvested and sorted again with a FACS Aria. The expression levels of IL-5
and IL-13 were determined by quantitative PCR.
Statistical Analyses
Unless otherwise specified, data show themean ± /+ SEM and were evaluated
for statistical significance using the two-tailed Student’s t test.
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